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Abstract 
Motivation. Knowledge about the clonal evolution of each tumor can inform driver-alteration 
discovery by pointing out initiating genetic events as well as events that contribute to the 
selective advantage of proliferative, and potentially drug-resistant tumor subclones. A necessary 
building block to the reconstruction of clonal evolution from tumor profiles is the estimation of the 
cellular composition of each tumor subclone (cellularity), and these, in turn, are based on 
estimates of the relative abundance (frequency) of subclone-specific genetic alterations in tumor 
biopsies. Estimating the frequency of genetic alterations is complicated by the high genomic 
instability that characterizes many tumor types. 
Results. Analysis of our mutation-centric model for genomic instability suggests that copy 
number variations (CNVs) that are commonly observed in tumor profiles can dramatically alter 
mutation-frequency estimates and, consequently, the reconstruction of tumor phylogenies. We 
argue that detailed accounting for CNVs based on profiles of multiple biopsies for each tumor 
are required to accurately estimate mutation frequencies. To help resolve this problem we 
propose an optimization algorithm—Chimæra: clonality inference from mutations across 
biopsies—that accounts for the effects of CNVs in multiple same-tumor biopsies to estimate both 
mutation frequencies and copy numbers of mutated alleles. We show that mutation-frequency 
estimates by Chimæra are consistently more accurate in unstable genomes. When studying 
profiles of multiple biopsies of a high-risk prostate tumor, we show that Chimæra inferences 
allow for reconstructing its clonal evolution. 
Data availability. Sequencing data is deposited in ENA project PRJEB19193 and source code 
in GitHub project Chimaera. 
Introduction 
Pan-cancer tumor profiling has identified recurrent alterations that are associated with tumor 
etiology at the loci of thousands of genes (Futreal, et al., 2004; Higgins, et al., 2007). Yet, despite 
this wealth of information, patient genomic profiles often fail to reveal tumorigenesis-driving 
alterations, and, consequently, the interpretation of genomic alterations remains a major 
challenge for personalized medicine efforts in oncology. Knowledge about tumor clonal evolution 
can point to genomic alterations that both contribute to tumorigenesis and indicate 
prognostically-relevant intratumoral variability (Fidler and Hart, 1982; Nowell, 1976). Specifically, 
clonal evolution—depicted as a phylogenetic tree in Figure 1A—can help identify alterations that 
play a role in tumor initiation as well as those that confer a selective advantage to altered tumor 
cells. In addition, information about the subclonal composition of tumors is essential for 
designing targeted therapies, since not all subclones may be targeted in the same way. Indeed, 
 tumor heterogeneity may hold the key to predicting tumor progression, sensitivity to a drug, and 
prognosis, as drug resistance and metastatic potential may vary between subclones (Boutros, 
et al., 2015).  
Current methods that rely on DNA-profiling to reconstruct tumor clonal evolution can be 
classified into two categories: methods that primarily rely on single-cell sequencing (Gao, et al., 
2016; Mann, et al., 2016; Suzuki, et al., 2015; Wang, et al., 2014) and those that computationally 
resolve mixtures of subclones from molecular profiles of tumors, i.e. profiles of pools of cells 
originating from a common malignant  lesion (Andor, et al., 2016; El-Kebir, et al., 2015; Niknafs, 
et al., 2015). Single-cell sequencing can produce more definitive estimates of the proportion of 
tumor cells that contain each genomic alteration (alteration frequency) and more complete 
profiles of tumor subclones including information about the co-occurrence of alterations in each 
subclone. The primary disadvantages of single-cell methods are operational—the availability of 
high-quality snap-frozen or fresh tumor samples that permit single-cell isolation, and the 
accuracy and cost associated with sequencing DNA from hundreds of single cells per tumor. 
Costs associated with single-cell library preparation may not decline as rapidly as the cost of 
sequencing, and accuracy is likely to remain an issue due to limited material availability in single 
cells. Moreover, the availability of tissue for single-cell isolation is not likely to improve as future 
sequencing technologies focus on profiling formalin-fixed paraffin-embedded (FFPE) tissues 
that are not fully compatible with single-cell isolation (Cieslik, et al., 2015; Getz and Ardlie, 2012).  
We are interested in improving methods for reconstructing clonal evolution from mutation profiles 
of primary tumors. In the absence of single-cell sequencing, we need to deconvolve mutation 
frequencies, alteration-subclone associations, and subclone cellularities from sequencing 
assays that average profiles across cellular ensembles (Figure 1B). One approach to improving 
the accuracy of this deconvolution is to profile multiple biopsies from the same tumor across time 
points (Wang, et al., 2014) or across tumor regions that may be selected for their variable 
 
Figure 1. Footprint of clonal evolution across tumor biopsies. (A) Tumor phylogeny composed of five 
dominant tumor subclones and wildtype (WT) cells—with no somatic mutations—that make up the 
cellular composition of four tumor biopsies (B). Subclones 3 and 5 were more proliferative—i.e. the 
proportion of these subclones (cellularity) in containing biopsies is greatest. (C) Failure to account for 
genomic instability can skew cellularity estimates because fractions of reads (mutated-read fractions) 
presenting each mutation in WES depend on the copy numbers of the alleles in both mutated and non-
mutated cells. Consequently, in genomically-stable tumors, biopsies from (B) will have mutated-read 
fractions that differ from those of (D) genomically unstable tumors with the same cellularities.  
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(Boutros, et al., 2015; 
Gundem, et al., 2015). 
While this approach may 
not be feasible for all tumor 
types, due to concerns 
about clinically unjustified 
strain to patients, it is a 
natural fit for high-risk 
patients with blood 
malignancies and some 
solid tumors, including 
prostate adenocarcinomas. 
The presence of multiple 
biopsies can benefit efforts 
to deconvolve cellularity 
and tumor phylogeny 
because, and especially if 
carefully collected, the 
clonal composition across 
regions of heterogeneous 
tumors is expected to be variable. Consequently, under the infinite-sites assumption (Jiao, et al., 
2014) where two genomic events may not target the same locus, genomic alterations that are 
specific to one tumor subclone will co-occur with the same frequency across biopsies. 
Focusing on single-nucleotide somatic variants (SNVs; or simply mutations), we describe the 
clonality problem as that of associating mutations with subclones and inferring ancestral 
relations between subclones. The goal of the resulting set-theoretic formulation, for each tumor, 
is to aggregate co-occurring mutations across biopsies, estimate the frequency of each 
aggregate in every biopsy, and identify partial orders across aggregates that are consistent 
across biopsies. When viewed this way, each subclone can be associated with a frequency 
vector that describes the proportion of cells containing its mutations in each biopsy. Establishing 
ancestral order between two subclones then depends on comparisons between their 
corresponding mutation frequencies. Note that subclone cellularity is a function of tumor 
phylogeny and mutation frequency: daughter subclones inherit mutations from ancestral 
subclones. Consequently, the cellularity and frequency of a subclone and one of its associated 
mutations can be 0 and 100%, respectively, if this mutation originated in an extinct ancestral 
subclone whose descendant subclones populated the profiled tumor.  
Our first challenge is to estimate mutation frequencies across biopsies. In cellular environments 
with stable genomes, where CNVs are few, accurate mutation-frequency estimation is a function 
of allele coverage. Mutation frequencies can be computed directly from sequencing evidence for 
the mutated allele—the fraction of reads (mutated-read fraction) that support the mutation as 
observed in whole-exome sequencing (WES) data. However, CNVs can affect mutation 
frequency estimates because the mutated-read fraction is affected by contributions from alleles 
in mutation-free cells as well as both the mutated and wildtype forms of the allele in mutated 
cells. Changes to the copy number of one of these allele contributors can alter the mutated-read 
fraction dramatically, and if not accounted for, will results in inaccurate mutation- frequency 
estimates (Figure 1C). In turn, errors in mutation-frequency estimates can translate to inaccurate 
phylogeny reconstruction (Figure 2).  
 
Figure 2. Small variations in mutation frequency estimates can impact 
the inference of ancestral relations. (A) Simulated tumor phylogeny, 
(B) subclone cellularities, and (C) frequencies of subclonal mutations 
across biopsies. (D) Ancestral relations between subclones can be 
inferred from comparisons of their frequency vectors: Subclone 4 
frequencies are greater than those of subclone 3 across all biopsies, 
but (E) errors in frequency estimates (red) can violate this relationship 
and complicate tumor-phylogeny reconstruction efforts.  
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 Here, we introduce a natural model for the effects of CNVs on mutated-read fractions in WES. 
We use this model as a basis for simulations with CNV distributions that are compatible with 
observations from The Cancer Genome Atlas (TCGA)-profiled primary breast and prostate 
adenocarcinomas (The Cancer Genome Atlas, 2012; The Cancer Genome Atlas, 2015). Data 
was simulated using synthetically generated phylogeny, including CITUP phylogenies (Malikic, 
et al., 2015), followed by the duplication or loss of sequencing reads according to simulated 
effects of CNVs. Attempts to estimate the frequencies and cellularities of mutations and 
subclones using ABSOLUTE (Carter, et al., 2012), AncesTree (El-Kebir, et al., 2015), EXPANDS 
(Andor, et al., 2014), and SCHISM (Niknafs, et al., 2015) revealed variable success rates, with 
some methods showing consistently poor accuracy. EXPANDS, which was designed for 
phylogeny reconstruction using one WES at a time, and ABSOLUTE, which is best known and 
most effective for estimating tumor purity, had consistently poor accuracy in our simulations. 
While SCHISM and AncesTree, which do not explicitly account for the full range of observed 
CNVs in tumors, were less accurate on simulations with CNVs. We concluded that explicit 
accounting for CNVs is required in order to approximate mutation frequencies accurately. 
To address this challenge and improve mutation-frequency estimation from WES of tumors with 
genomic instability, we developed Chimæra: clonality inference from mutations across biopsies. 
Chimæra relies on multiple biopsies for the same tumor to, first, approximate CNVs and mutation 
frequencies; then, identify mutations with similar approximate frequencies and associate them 
with subclones; and, finally, to estimate the true frequencies of these mutations and the 
associated subclones. As is the case for estimates made by SCHISM, ABSOLUTE and other 
methods, Chimæra is not able to produce frequency estimates for all mutations. Frequencies 
are not estimated for mutations that could not be associated with subclones, and these estimates 
remain an open problem. Finally, to demonstrate that Chimæra is able to reconstruct subclones 
from tumor profiles we produced Chimæra-inferred subclones and resulting phylogeny from 
profiles of ten biopsies taken from a castration-resistant prostate cancer (CRPC) tumor. 
Methods  
We begin by formulating the phylogeny reconstruction problem in set-theoretic terms, which 
leads to a natural model for the effects of CNVs on mutated-read fractions in WES. We describe 
our methodology for simulating WES tumor profiles, as well as our efforts to deconvolve mutation 
frequencies from simulated data using ABSOLUTE, AncesTree, EXPANDS, SCHISM, and 
Chimæra. Finally, to demonstrate that Chimæra can be effectively applied to clinical data, we 
describe a reconstructed phylogeny from WES profiles of ten same-tumor CRPC biopsies.  
Phylogeny reconstruction problem 
Let Π = {𝑎, 𝑏, 𝑐,⋯ , 𝑛} denote the set of mutations identified across a set of profiled biopsies 𝑆. 
The mutation burden in any given cell is given as a subset of Π, 𝛽 ⊆ Π, or as an element of the 
power set over Π, 𝒫(Π) or 𝒫 for short; i.e. 𝛽 ∈ 𝒫 is a specific mutation ensemble that 
characterizes a tumor subclone. We denote the cellularity of 𝛽 and its corresponding subclone 
in biopsy 𝑠 ∈ 𝑆 as 𝑃𝛽
𝑠, and the frequency of mutation 𝑎 ∈ 𝛽 in biopsy 𝑠 as 𝑃𝑎
𝑠 = ∑ 𝑃𝛽
𝑠
{𝛽|𝛽∈ 𝒫,𝑎∈𝛽} . 
Consequently, ∑ 𝑃𝛽
𝑠
𝛽∈ 𝒫 = 1 and the assignment 𝐴 = {𝑃𝛽
𝑠|𝛽 ∈  𝒫, 𝑠 ∈ 𝑆} produces a solution to our 
clonality reconstruction formulation.  
Mutation frequencies  
As defined above, for a mutation 𝑎 in biopsy 𝑠 ∈ 𝑆, 𝑃𝑎
𝑠 denotes the frequency of cells in 𝑠 with 
mutation 𝑎. The total copy number 𝐶𝑠 of the allele targeted by the mutation can be estimated 
from WES data. 𝐶𝑠 is composed of the copy numbers of the allele in cells that lack 𝑎, 𝛿𝑠; the 
copy number of the wildtype allele in mutated cells, 𝛿𝑠
0; and the copy number of the mutated 
 allele, 𝛿𝑠
𝑎 (Figure 3). Adopting the infinite-sites 
assumption, we denote the mutated-read fraction—
the fraction of reads reflecting the mutated vs. wildtype 
allele in a WES profile—in sample 𝑠 as 𝑓𝑠. Then, we 
can form the following equations (Eq. 1 and Eq. 2). 
𝐶𝑠 = 2𝛿𝑠(1 − 𝑃𝑎
𝑠) + 𝑃𝑎
𝑠(𝛿𝑠
0 + 𝛿𝑠
𝑎) Eq. 1 
𝑓𝑠 =
𝑃𝑎
𝑠𝛿𝑠
𝑎
𝐶𝑠
    Eq. 2 
Chimæra  
Chimæra proceeds in three steps. First, mutation 
frequencies are estimated from sequencing and CNV 
data in each biopsy; then, mutations with similar 
frequency vectors (across biopsies) are clustered 
together to form subclones; and finally, mutation 
frequencies and CNVs for these alleles are refined 
using an optimization process. The optimization 
assumes that all clustered mutations that are 
associated with the same subclone have the same 
frequency in each tumor biopsy and that 𝛿𝑠
𝑎—the 
average copy number of the mutated allele—is the 
same across all biopsies from the same tumor.  
A first approximation. We first approximate 𝛿𝑠
𝑎 by 
accounting for tumor purity, i.e., the fraction of tumor 
cells in the biopsy, and assuming that the allele’s average copy number in tumor cells—whether 
mutated or not—is fixed. Let 𝜑 be the purity of the biopsy, then Eq.2 can be rewritten as follows: 
𝑓𝑠 =
𝑃𝑎
𝑠𝛿𝑠
𝑎𝜑
𝐶𝑠𝜑+2(1−𝜑)
   Eq. 3, 
𝐶𝑠, in turn, can be approximated from the observed copy number 𝐶𝑜𝑏𝑠 as given in Eq. 4; 𝐶𝑜𝑏𝑠 can 
be estimated using additional biochemical assays, genomic sequencing, or through 
computational analysis of WES data (Koboldt, et al., 2012). 
𝐶𝑠 =
𝐶𝑜𝑏𝑠−2(1−𝜑)
𝜑
   Eq. 4 
The simplifying assumption that the allele’s average copy number in tumor cells in each biopsy 
is equivalent produces a first approximation for its mutation frequency (Eq. 5). This constraint is 
later removed in the optimization process that follows. 
𝑃𝑎
?̃? =
2𝑓𝑠𝐶𝑜𝑏𝑠
𝐶𝑜𝑏𝑠−2(1−𝜑)
   Eq. 5. 
Subclone reconstruction. Approximate mutation frequency vectors (Eq. 5) are then clustered 
using tclust (Fritz, et al., 2012) with the number of clusters selected by optimizing intra-cluster 
entropy or the sum of square errors (SSE), and using a variety of optimization methods including 
the Elbow method, Gaussian mixture decomposition (GMD), and SD index (Celeux and Govaert, 
1995; Kovács, et al., 2005; Krzanowski and Lai, 1988). We evaluated each clustering methods 
on simulated data; e.g., in our simulations, SSE with the Elbow optimization method produced 
the best results for Chimæra frequency estimates, while SD index was the best for SCHISM. 
Each mutation cluster formed a subclone representation and was used to infer subclone 
frequencies and copy number estimates for each mutated allele. 
 
Figure 3. Our mutation-centric model 
for the effects of CNVs on mutated-read 
fractions in WES. In each biopsy 𝑠, the 
mutated-read fraction is a function of the 
true mutation frequency 𝑃𝑎
𝑠 and (1) the 
copy numbers of the allele in all profiled 
cells—tumor and WT—that lack this 
mutation, 𝛿𝑠, and (2) the copy numbers 
of the wildtype and the mutated allele in 
tumor cells with the mutation, 𝛿𝑠
0, 𝛿𝑠
𝑎. 
Clonality and copy number of a mutated allele across biopsies
Biopsy I Biopsy II
Biopsy III Biopsy IV
 Frequency and copy number inference. Focusing on subclone 𝛽 ∈ 𝒫, EQ. 3 describes a 
relationship between the frequencies and copy numbers of mutations in 𝛽, as given by Eq. 6. 
Here, ℬ𝑠𝑎  ∈ ℝ
|𝑆|,|𝛽| is fully determined from observations from sequencing assays, including the 
estimated copy numbers and observed mutated-read fractions for each subclone mutation. 
𝑃𝑎
𝑠δs
a = fs (Cs +
2
𝜑
− 2) ≡  ℬsa,   ∀  𝑎 ∈ 𝛽, 𝑠 ∈ 𝑆. Eq. 6 
Eq. 6 mutation frequencies and copy numbers cannot be analytically decoupled, but same-
subclone mutations are expected to have the same frequencies, i.e. 𝑃𝑎
𝑠 = 𝑃𝑏
𝑠 ∀  𝑎, 𝑏 ∈ 𝛽. To 
simplify the optimization problem, we assume that copy numbers of each mutation are the same 
in each same-tumor biopsy, i.e.  δs𝑖
a = δs𝑗
a ∈ [0, 𝐶𝑁]  ∀ s𝑖 , s𝑗 ∈ 𝑆, where 𝐶𝑁 is a fixed upper bound 
for the copy number; 𝐶𝑁 = 15 in our simulations and WES analysis. while we expect that this 
assumption will introduce some errors to the approximation of δs
a, it will have limited effects on 
the selection of optimal mutation frequencies because the variability of copy number averages 
for the mutated allele across biopsy is expected to be low. We note that while this assumption 
may be appropriate for tumor profiles, it is violated by our simulations, which produced variable 
copy numbers for the same mutated allele across biopsies. Consequently, we pose an 
optimization problem based on Eq. 6, producing the following outer product of vectors ?⃑?  and δ⃑ : 
min‖?⃑? ⊗ δ⃑ − ℬ‖
2
 , ∀𝑎 ∈ 𝛽, 𝑠 ∈ 𝑆; 0 ≤ δ𝑎 ≤ 𝐶𝑁 , 0 ≤ 𝑃𝑆 ≤  1,  ∀𝑎 ∈ 𝛽, ∀𝑠 ∈ 𝑆. Eq. 7 
Where ?⃑?  is the mutation 
frequency vector across 
biopsies for all mutations in 
𝛽 (|?⃑? |=|𝑆|); δ⃑  is the copy-
number vector for all 
mutations in 𝛽 (|δ⃑ |=|𝛽|); and 
ℬ is as given in Eq. 6. We 
used limited-memory 
Broyden–Fletcher–
Goldfarb–Shanno 
optimization (Sheppard, et 
al., 2008) to find locally 
optimal solutions to the 
optimization posed in Eq. 7. 
Simulation of WES data  
WES simulations were 
based on phylogenies and 
associated cellularity 
matrices that describe 
ancestral relations between 
6 to 12 subclones. These 
were either generated by us 
(see Figures 4A,B, Table S1 
for representative 
phylogenies) or adapted 
from CITUP. Each subclone 
was associated with 20 to 
 
Figure 4. Our synthetic data generation and a comparison of 
simulated CNV distributions to those that were observed in tumors. 
(A) Representative phylogenies and (B) a representative cellularity 
matrix; see Table S1 (C) Density plots of average copy numbers 
across profiles of TCGA prostate (PRAD) and breast (BRCA) tumors, 
and our CRPC tumor. PRAD1 and PRAD2 show genome-wide CNV 
distributions in each of two PRAD tumors, while PRAD and BRCA 
distributions are taken across genes and tumors; CNVs ranged from 0 
to >260x. (D) Simulated CNVs ranged from 0 to 15x. 
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 50 somatic mutations, and each somatic mutation was associated with a trio of copy numbers—
𝛿𝑠, 𝛿𝑠
0, and 𝛿𝑠
𝑎—that were taken from truncated normal distributions with means µ ∈ {1,2,3}, 
where µ = 1 corresponds to no copy number changes, and standard deviation σ ∈ {0,1,2,3}; σ =
0 was used only when µ = 1. The resulting copy numbers model a range of genomic instability 
conditions that was in line with observed copy number changes in PRAD and BRCA tumors 
(Figure 4C,D). We assumed no linkage between simulated CNVs of any mutations. In addition, 
we added up to 10% of wildtype reads for all simulated mutations to account for the potential 
inclusion of non-tumor cells in the assay (WT subclone in Figure 1A). Total coverage for each 
allele—i.e. the number of reads covering both wild-type mutated genomic position—was taken 
by sampling mutation coverage values from our CRPC tumor biopsies. Finally, once idealized 
counts were available for both mutated and wild-type alleles, noise was added to simulate 
duplication or loss of up to 5% of the observations according to a uniform distribution. Each 
simulation was repeated to produce six biopsies per tumor using a distinct cellularity vector for 
each biopsy (as depicted in Figure 4A,B). The availability of six biopsies per tumor increases the 
likelihood that mutations can be aggregated and subclone mutation frequencies can be 
compared to infer ancestral relations. We note that while our CRPC tumor was profiled at ten 
regions, setting a six-biopsy minimum will exclude the profiling of many tumor types using our 
methods; this was a compromise between clinical feasibility and power to infer mutation 
frequencies and phylogenies.  
Profiling and analysis of 10 CRPC biopsies  
To test our ability to infer mutation frequencies and ancestral relations between subclones based 
on clinical profiles, we profiled 10 castrate-resistant prostate cancer (CRPC) tumor biopsies 
(Figure 5). The Specimen was collected at the Department of Pathology and Molecular 
Pathology, University Hospital Zurich, Switzerland as previously described (Mortezavi, et al., 
2011) with the approval of Cantonal scientific ethics committee Zurich, approval number KEK-
ZH-No. 2014-0007, and with informed consent by the patient. Tumor regions were selected for 
heterogeneous histological presentation by an experienced uropathologist (PJW). DNA from 
peripheral blood and FFPE punches (10 cylinders with diameter of 0.6 mm) was isolated with 
the Maxwell 16 LEV 
Blood DNA kit (Promega, 
AS1290) and Maxwell 16 
FFPE Tissue LEV DNA 
Purification Kit (Promega 
AS1130), respectively, 
according to 
manufacturer’s  
recommendations; 300μl 
of blood collected in a 
BD Vacutainer K2 
(EDTA 18.0mg) tube 
was added to 30μl of 
Proteinase K solution 
(final concentration 2 
mg/ml) and 
subsequently mixed with 
300μl lysis buffer, 
vortexed and incubated 
for 20 min at 56°C. FFPE 
 
Figure 5. Profiled CRPC regions. Overview of four hematoxylin-eosin 
stained histology slides with 10 profiled areas (left); and zoomed-in 
versions (right) that portray the histological heterogeneity of this tumor. 
These CRPC regions were profiled by deep WES. 
 cylinders were deparaffinised with xylene, washed twice with ethanol, dried 10 min at 37°C and 
re-suspended in 200μl incubation buffer containing 2mg/ml Proteinase K. Samples were 
incubated overnight at 70°C and mixed with 400μl lysis buffer. Lysates from both, blood and 
FFPE tissues, were transferred to well 1 of the supplied cartridge of the corresponding kit and 
DNA was automatically purified and eluted in 30μl Tris-buffer, pH 8.0 by the Maxwell instrument. 
Each biopsy was profiled using Agilent SureSelect Whole Exome Enrichment, v6 (58 Mbp) and 
2 × 75bp paired-end reads were used for optimal performance on a HiSeq 4000 (Illumina). 
Mutation calling was followed by protocols established by TCGA and ExAC (Lek, et al., 2016; 
The Cancer Genome Atlas, 2015). Reads were aligned to hg19 using BWA (Li and Durbin, 
2010), and variants were called with GenomeAnalysisTK, MuTect (Cibulskis, et al., 2013), Picard 
MarkDuplicates, and additional post-processing utilities from GATK including BaseRecalibrator. 
FastQ files were deposited in EBI’s ENA project PRJEB19193. Predicted mutations are given in 
Table S2; mutations were annotated with estimated read fractions and estimated CNVs by 
VarScan using default parameters and after setting the maximum amplification to 15x (Koboldt, 
et al., 2012). Mutations that were present in fewer than 3 biopsies or supported by fewer than 3 
reads were discarded. A total of 355 mutations were used as input for inference methods.  
Results  
We describe our efforts to evaluate method accuracy on simulated data and to reconstruct 
phylogeny based on WES profiles of 10 CRPC biopsies. 
Accuracy of mutation-frequency estimation based on simulated data 
We compared the accuracy of EXPANDS, ABSOLUTE, SCHISM, AncesTree, and Chimæra on 
simulated data, as described in Methods. Phylogeny reconstruction success and clonality-
inference accuracy by EXPANDS and ABSOLUTE were the lowest. EXPANDS relies on single 
biopsies, and when evaluated on phylogenies that were composed of as few as 3 tumor 
subclones, EXPANDS-reconstructed phylogenies from profiles of same-tumor biopsies (both 
simulated and collected from the clinic including the CRPC reported on here) had few common 
ancestral inferences and performance was poor in every tested simulated instance. In contrast, 
SCHISM-reconstructed phylogenies from synthetic constructions with 3 tumor subclones were 
accurate in 100% of tested instances. ABSOLUTE can process profiles of multiple biopsies per 
tumor and has good accuracy for inferring tumor purity in our synthetic data. However, when 
using default parameters, errors in ABSOLUTE frequency-inferences were more than double 
those of SCHISM. Parameter optimization through human intervention consistently improved its 
accuracy, but it remained less accurate than SCHISM. Moreover, the degree of human 
intervention that this required was not compatible with large-scale benchmarking. Consequently, 
we focused on accuracy comparisons between inferences by SCHISM, AncesTree, and 
Chimæra (as given in Figure 6), and excluded EXPANDS and ABSOLUTE from further analyses. 
AncesTree accepts no external input when estimating mutation frequencies, but SCHISM and 
Chimæra can be guided by externally-inferred mutation clusters. SCHISM’s implementation 
includes its own selected clustering methods, and these were also used to compare accuracy. 
We clustered mutations with tclust based on five optimization methods: ElbowSSE, Entropy, 
GMD, Mclust, and SDIndex. We compared the accuracy of methods and pipelines on 2000 
simulated assays, including both simulated assays with and without modelled genomic instability 
(varying mutation copy numbers). The accuracy of SCHISM estimates was better on average 
than that of AncesTree, but it was relatively sensitive to clustering optimization methods, with 
SDIndex outperforming other methods, including those included in SCHISM’s implementation. 
Comparatively, Chimæra estimates were less dependent on clustering methods and significantly 
outperformed estimates by SCHISM with SDIndex (p<1E-16 by U test); Chimæra performance 
 was marginally best using 
ElbowSSE clustering 
(Figure 6A). A comparison 
of SCHISM and Chimæra 
on CITUP-simulated data 
(no CNVs) suggested 
similar accuracy for 
SCHISM-SDIndex and 
Chimæra-ElbowSSE 
(p<0.06, based on 700 sim 
assays; Figure 6B).  
Inference accuracy, for both 
SCHISM and Chimæra, was 
anti-correlated with the level 
of genomic instability, which 
followed truncated normal 
distributions with varying 
means and variances 
(Figure 6C, see Methods for 
data generation). To better 
understand mutation-level 
behaviour, as opposed to 
the genome-level 
comparisons in Figure 6C, 
we rescued individual 
mutations from each 
simulation and compared 
accuracy, mutation by 
mutation, as a function of 
their simulated copy 
numbers (Figure 6D). The 
result suggests similar 
Chimæra accuracy across 
copy numbers. We note that 
many mutations were 
eliminated from the 
evaluation by both the SCHISM and Chimæra pipelines. In total, only 40% and 20% of mutations 
were assigned frequencies by Chimæra and SCHISM, respectively; these proportion were 
independent of mutation copy numbers. While Chimæra assigned frequencies to all clustered 
mutations, SCHISM did not successfully estimate mutation frequencies for some simulated 
genomes. Accuracy comparisons in Figure 6 were made using only those mutations that had 
assigned frequencies by all methods.  
In its totality, our analysis suggests that, at least under our model, mutation frequency estimation 
is more challenging for genomes with high copy-number variability. Chimæra inference accuracy 
for simulated genomes where all mutations had consistently low or consistently high copy 
numbers was relatively high. This is in part due to Chimæra’s iterative process, where success 
in mutation clustering is followed by an optimization process that can correct for consistently 
high or consistently low mutation copy numbers.  
 
Figure 6. Accuracy on simulated data. (A) Accuracy of mutation-
frequency estimates by AncesTree (purple), SCHISM (red) and 
Chimæra (green) on simulated WES data from genomes with varying 
mutation copy numbers; SCHISM and Chimæra were evaluated using 
multiple clustering methods with SDIndex (SCHISM) and ElbowSSE 
(Chimæra) producing top accuracy, respectively. (B) The gap 
between SCHISM and Chimæra accuracy was narrower on simulated 
data with no copy number variations. (C) Accuracy was inversely 
correlated with genomic instability, which was measured here as the 
coefficient of variation of the distributions used to simulate CNVs in 
each simulated WES profile; SCHISM with SDIndex clustering 
outperformed AncesTree inferences. (D) Evaluated independently, 
mutation copy numbers had relatively little effect on Chimæra 
accuracy. We report results for Chimera with ElbowSSE and 
SCHISM with SDIndex, but these are representative and resemble 
results with other clustering methods. Standard errors are reported. 
Mean Error is the mean of L1 distances between true and estimated 
mutation frequencies after normalizing for the number of biopsies. 
 Phylogeny inference in CRPC  
To test our ability to infer 
mutation frequencies and 
ancestral relations between 
subclones using clinical data, we 
profiled ten biopsies of a single 
castrate-resistant prostate 
cancer (CRPC) tumor (Figure 5). 
CRPCs are high-risk prostate 
tumors that are known to have 
high genomic instability 
(Robinson, et al., 2015). Each of 
these biopsies was profiled and 
analyzed as described in 
Methods, producing a total of 355 
mutations that were used as 
input to SCHISM, ABSOLUTE 
and Chimæra (Table S2). 
SCHISM did not produce 
frequency estimates for any of 
the mutations in Table S2. 
ABSOLUTE, following repeated parameter optimization steps by PC (author), produced 
frequency estimates for 21 mutations, resulting in 4 predicted subclones; mutations in 3 of these 
subclones had high frequencies in at least one biopsy, but ancestral relations between these 
subclones could not be inferred. Chimæra inferred frequencies for 31 mutations that were 
clustered into 8 subclones, and these formed a unique phylogeny and resulting cellularity 
estimates. A summary of Chimæra inferences is given in Figure 7 with subclones, and both 
mutation frequencies and cellularities are given in Table S2.  
Chimæra inferred potentially initiating mutations that targeted 7 genes, and identified a chain of 
3 subclones that followed in a later stage in tumor evolution; the earliest 2 subclones were nearly 
eliminated from the tumor, suggesting that the following 2 subclones had a selective advantage. 
The inference suggests a diverging event associated with subclone 5 and 7 mutations, which 
resulted in the proliferation of new subclones. Interestingly, the analysis identified genes that 
were targeted by multiple mutations, with these mutations inferred from multiple subclones and 
specific evolutionary sequence of this tumor (ZNF778 and ANKRD36B; see Figure 7).  
Discussion 
We sought to develop a methodology to improve the accuracy of tumor phylogeny reconstruction 
from tumor WES data by improving mutation-frequency estimates when multiple profiles of the 
same tumor are available. Mutation-frequency estimates are particularly challenging in the face 
of high genomic instability, which is characteristic to many tumor types, including the high-risk 
prostate cancer tumor whose profiling was reported on here. Our proposed method, Chimæra, 
is suitable for analyzing tumor profiles across multiple time points and across multiple tumor 
regions and can be easily modified to process both types of data, but here we focused the 
discussion on the latter. In addition, while we focused on single nucleotide variants, our methods 
can be extended to consider other types of genomic alterations. 
We outlined the challenges involved in estimating mutation frequencies from WES of genomes 
with high genomic instability—where the copy numbers of mutations can widely vary. We 
showed that, even for EXPANDS, which uses the copy number of mutations to infer phylogeny, 
 
Figure 7. Reconstructed tumor phylogeny. (A) Chimæra 
inferred 8 CRPC subclones that implied a recently diverging 
phylogeny, with subclones 3-5 the most proliferative according 
to the resulting (B) cellularity matrix. (C) Mutated genes and 
mutation average frequencies across biopsies in each subclone. 
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 the accuracy of mutation frequency estimates, cellularities, and phylogeny reconstruction using 
single biopsies was very poor. Our own investigation suggests that the task is often impossible 
on simulated assays with varying mutation copy numbers. Consequently, we elected to rely on 
multiple biopsies per tumor to improve mutation-frequency estimation. We showed that even 
when profiles of multiple biopsies are available, methods that do not explicitly account for the full 
range of copy number variability produce inconsistent results with often poor accuracy.  
Chimæra is able to improve mutation-frequency estimates by harnessing added information from 
multiple profiles and by directly accounting for the influence of CNVs on observations from WES. 
Chimæra’s advantage was clearly observed in simulated data, where its performance was the 
most consistent, and its accuracy the greatest. Interestingly, while Chimæra was able to estimate 
mutations frequencies with relatively high accuracies even for mutations with very high and very 
low copy numbers, its performance declined for the most unstable genomes where mutation 
copy numbers varied widely. Our CRPC tumor, which displays high genomic instability, 
exemplified this problem. Chimæra estimated frequencies for only 40% of mutations in simulated 
data and only 10% of mutations in our CRPC-biopsy profiles. This difference is likely to be due 
to the number of mutations associated with the formation of each subclone and suggests that 
future work should further vary this number.  
In conclusion, our results suggest that accurate mutation-frequency and cellularity inference is 
possible using profiles of multiple biopsies per tumor. Improving current estimates further—both 
in terms of accuracy and by including more mutations in estimates—remains an open challenge. 
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